Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 211Lung Neoplasms 77Triple Negative Breast Neoplasms 67Breast Neoplasms 67Ovarian Neoplasms 53Squamous Cell Carcinoma of Head and Neck 49Small Cell Lung Carcinoma 47Fallopian Tube Neoplasms 34Endometrial Neoplasms 34Neoplasms 31Parkinson Disease 4, Autosomal Dominant Lewy Body 28Neoplasm Metastasis 28Head and Neck Neoplasms 24Prostatic Neoplasms 20Esophageal Neoplasms 18Carcinoma 18Urinary Bladder Neoplasms 16Colorectal Neoplasms 16Uterine Cervical Neoplasms 14Oropharyngeal Neoplasms 14Carcinoma, Transitional Cell 14Carcinoma, Squamous Cell 14Esophageal Squamous Cell Carcinoma 12Brain Neoplasms 12Stomach Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Mouth Neoplasms 9Laryngeal Neoplasms 9Advanced Solid Tumors 9

Interventions

pembrolizumab 2sacituzumab govitecan 1enzalutamide 1atezolizumab 1abiraterone 1Penfluridol 1PT-100 dipeptide 1PM 01183 1Nivolumab 1Ipilimumab 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Carboplatin × 1 year × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡